CTRI/2011/07/001919
Not yet recruiting
未知
Intravitreal Pegaptanib for treatment of Choroidal Neovascularisation secoundary to Pathologic Myopia-A Pilot Study - INJECT
VPrasad Eye Institute0 sites20 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- VPrasad Eye Institute
- Enrollment
- 20
- Status
- Not yet recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.Should be willing to participate in the trial.
- •2\.Age less than 55 years.
- •3\.Best corrected visual acuity (BCVA) score of at least 5 letters (20/200\), as assessed by ETDRS chart.
- •4\.Myopia of greater than or equal to 6 Diopters.
- •5\.Fluorescein angiographic documentation of CNV.
Exclusion Criteria
- •1\.Ocular causes, or other ocular disorders leading to vision loss.
- •2\.Maculopathy not related to pathologic myopia.
- •3\.Pregnancy, lactation.
- •4\.Not willing to provide an informed consent.
- •5\.History of previous macular laser including PDT.
- •6\.Other forms of therapy including intravitreal injections.
- •7\.History of intraocular surgery in the past 3 months.
- •8\.Anticipated cataract surgery in the next 6 months.
- •9\.Any active infection or inflammation in the eye.
- •10\.Cases where good quality imaging is not possible, either due to hazy media or extremely high myopia.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Treatment of a chorioretinal disease characterized by alterations in the elastic lamina of the Bruch's membrane, and which typically manifest themselves as streaks radial departure from the optic nerveEUCTR2014-000986-30-ITIRCCS Ospedale San Raffaele U.O. Oculistica
Active, not recruiting
Phase 1
Intravitreal Aflibercept (Eylea®) for therapy of choroidal neovascularization and fibrovascular proliferation in patients with Pseudoxanthoma elasticumChoroidal neovascularizations and fibrovascular proliferations in patients with Pseudoxanthoma elasticumMedDRA version: 20.0Level: PTClassification code 10037150Term: Pseudoxanthoma elasticumSystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Eye Diseases [C11]EUCTR2014-005263-33-DEMedizinische Fakultät der Universität Bonn15
Withdrawn
Not Applicable
Intravitreal Pegaptanib in Treatment of Choroidal Neovascularisation Secondary to Pathologic MyopiaMyopic Choroidal Neovascular MembraneNCT01218230L.V. Prasad Eye Institute
Not yet recruiting
Phase 3
To investigate the role of Intravitreal Aflibercept (Eylea) in the treatment of patients whose wet Age related Macular degeneration is not adequately controlled with conventional anti VEGF (intravitreal Avastin or Lucentis) treatment.ACTRN12613001020774Greenlane Clinical Centre Auckland District Health Board50
Active, not recruiting
Phase 1
Re-treatment with intravitreal application of ranibizumab guided by morphological macular changes documented by optical coherence tomography (OCT) in patients with macular edema due to branch retinal vein occlusiomacular edema secondary to branch retinal vein occlusion (BRVO)MedDRA version: 18.1Level: LLTClassification code 10054467Term: Macular edemaSystem Organ Class: 100000004853MedDRA version: 18.1Level: LLTClassification code 10038906Term: Retinal vein branch occlusionSystem Organ Class: 100000004853Therapeutic area: Diseases [C] - Eye Diseases [C11]EUCTR2012-005439-10-DEniversity of Leipzig Ritterstr. 26, 04109 Leipzig18